Manage Account
Change Password
Sign Out
UserName
Profession Email
Profession Email
|
Indications/Uses
Listed in Dosage.
|
|
Dosage/Direction for Use
Adult : PO Menorrhagia 2.5-10 mg/day for 5-10 days on days 16-21 of the menstrual cycle. Repeat for 2 cycles. Mild to moderate endometriosis 10 mg 3 times/day. As progestogen component in menopausal HRT Dosage depends on oestrogen component of therapy, several regimens are used: 1.5 mg, 2.5 mg or 5 mg/day; 5 or 10 mg/day for 12-14 days of a 28-day cycle; 20 mg/day for 14 days of a 91-day cycle. Breast cancer 0.4-1.5 g/day. Max: 2 g/day. Palliation of endometrial and renal carcinoma 200-600 mg/day. Palliation of prostatic carcinoma 100-600 mg/day. Secondary amenorrhoea 2.5-10 mg/day for 5-10 days. Repeat for 3 cycles. IM Endometriosis 50 mg/wk. Contraception 150 mg 12 wkly. Breast cancer 0.5-1 g/day for 1st 4 wk. Maintenance 0.5 g twice wkly. Palliation of endometrial and renal carcinoma Initial: 0.4-1 g/wk. Reduce if needed, maintenance may be as low as 0.4 g/mth. Palliation of prostatic carcinoma 0.5 g twice wkly for 1st 3 mth. Maintenance: 0.5 g/wk. SC Contraception; Endometriosis 104 mg 12-14 wkly.
|
|
Dosage Details
Intramuscular
Endometriosis Adult: 50 mg wkly or 100 mg every 2 wk. Intramuscular Contraception Adult: 150 mg every 12 wk. Intramuscular Palliative treatment of endometrial and renal carcinoma Adult: Initially 0.4-1 g wkly. Reduce as necessary, maintenance may be as low as 0.4 g mthly. Intramuscular Palliative treatment of prostatic carcinoma Adult: 0.5 g twice wkly for first 3 mth. Maintenance 0.5 g wkly. Intramuscular Breast cancer Adult: 0.5-1 g daily for first 4 wk. Maintenance 0.5 g twice wkly. Oral Palliative treatment of endometrial and renal carcinoma Adult: 200-600 mg daily. Oral Mild to moderate endometriosis Adult: 10 mg tid. Oral Breast cancer Adult: 0.4-1.5 g daily. Max: 2 g daily. Oral Progestogen component in menopausal hormonal replacement therapy Adult: Dosage dependant on oestrogen component of therapy, several regimens are used: 1.5 mg, 2.5 mg or 5 mg daily; 5 or 10 mg daily for 12-14 days of a 28-day cycle; 20 mg daily for 14 days of a 91-day cycle. Oral Menorrhagia Adult: 2.5-10 mg daily for 5-10 days starting on the 16th-21st day of the menstrual cycle. Repeat for 2 cycles. Oral Palliative treatment of prostatic carcinoma Adult: 100-600 mg daily. Oral Secondary amenorrhoea Adult: 2.5-10 mg daily for 5-10 days. Repeated for 3 cycles. Subcutaneous Contraception, Endometriosis Adult: 104 mg every 12-14 wk.
|
|
Administration
May be taken with or without food. Incidence of minor indigestion may increase as dose increases. Take w/ meals if necessary.
|
|
Contraindications
Thromboembolic disorders; cerebral apoplexy; severe hepatic dysfunction; undiagnosed vaginal bleeding, incomplete abortion, hormone-dependent carcinoma; pregnancy.
|
|
Special Precautions
Patients with depression, DM, epilepsy, asthma, migraine, hypertension, renal or cardiac dysfunction. Monitor patient closely for loss of vision, proptosis, diplopia and thromboembolic disorders. Lactation.
|
|
Adverse Reactions
Depression, fluid retention. Fatigue, insomnia, dizziness, headache, nausea; breast tenderness; wt gain/loss, anorexia; cholestatic jaundice; pain at Inj site.
Potentially Fatal: Thrombophlebitis and pulmonary embolism. |
|
IM/Parenteral/PO/SC: X
|
|
Drug Interactions
Aminoglutethimide and enzyme-inducing drugs (e.g. carbamazepine, griseofulvin, phenobarbital, rifampicin, phenytoin) may reduce plasma concentrations leading to reduced efficacy. Additional measures required when medroxyprogesterone is used for contraception during coadministration with these drugs.
|
|
Lab Interference
Altered thyroid and liver function tests.
|
|
Action
Description: Medroxyprogesterone is a synthetic progestogen which converts the proliferative phase of the endometrium into secretory phase. It has some androgenic and anabolic activities but no oestrogenic effects. Parenteral use leads to inhibition of pituitary gonadotropins, thus preventing follicular maturation and ovulation.
Pharmacokinetics: Absorption: Well absorbed from the GIT (oral). Distribution: Enters the breast milk. Protein-binding: Highly bound to albumin. Metabolism: Hepatic. Excretion: Via the urine and faeces (as glucuronide conjugates); Elimination half-life: 24-30 hrs (oral), 50 days (IM). |
